LYRA THERAPEUTICS INC (LYRA) Stock News

USA - Nasdaq - NASDAQ:LYRA - US55234L2043 - Common Stock

4.27 USD

-0.23 (-5.11%)

Last: 12/5/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

LYRA Latest News, Press Relases and Analysis

All

Press Releases

23 days ago - By: Zacks Investment Research - Mentions: IGC

Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates

23 days ago - By: Lyra Therapeutics

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

25 days ago - By: Zacks Investment Research - Mentions: ASRT

Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates

a month ago - By: Zacks Investment Research - Mentions: HRTX

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

2 months ago - By: Benzinga - Mentions: LIXT SSKN ENTX GNPX ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

2 months ago - By: Stocktwits - Mentions: DFAS VTI

Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate

4 months ago - By: The Motley Fool

Lyra Therapeutics Posts 85% Q2 Loss Drop

6 months ago - By: Benzinga

Is the Market Bullish or Bearish on Lyra Therapeutics?

2 months ago - By: Lyra Therapeutics

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

4 months ago - By: Zacks Investment Research - Mentions: VVOS

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: Lyra Therapeutics

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Zacks Investment Research - Mentions: HRTX

Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates

5 months ago - By: Lyra Therapeutics

Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

6 months ago - By: Zacks Investment Research - Mentions: LXRX AMRN

Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success

6 months ago - By: Yahoo Finance - Mentions: LUMN HAL MPC PSX ...

Why Lumen Technologies, Inc. (LUMN) Crashed On Wednesday

6 months ago - By: Stocktwits - Mentions: IWM VTI MSFT

Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled

6 months ago - By: Lyra Therapeutics

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)